article thumbnail

ACE Inhibitor Not Protective Against Heart Damage from Chemotherapy

DAIC

The PROACT study reported no impact on cardiotoxicity biomarkers or secondary endpoints related to heart function among patients who took high doses of enalapril, an ACE inhibitor, along with high doses of anthracyclines. The mean dose of enalapril among those who were randomized to take the ACE inhibitor was 17.7mg.

article thumbnail

50 Shades of T

EMS 12-Lead

For a detailed review of deWinter OMI visit this post-- [link] Dr. Stephen Smith provides an academic hypothesis concerning the true underlying physiology of deWinter occlusion here-- [link] The clinical significance of HATW's can be found here-- [link] Crews administered 324 mg of ASA and a total of 0.12